drugset / Trial / NCT00421122

Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD

NCT00421122

Phase 3 Completed 315 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindTreatment

Summary

This study aims at evaluating efficacy and safety of Symbicort® Turbuhaler® in Chinese COPD patients as defined by GOLD treatment guidelines in order to obtain an approval for indication of COPD from Chinese State Food and Drug Administration.

Timeline

Start
2006-09
Primary completion
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 200 ug Inhaled
Subject budesonide/formoterol Unknown Inhaled
Background Terbutaline Small molecule Inhaled